Tweets
Don't miss a single moment of #EULAR2026—RheumNow is bringing you comprehensive, real-time coverage from June 3-6. Our trusted global faculty will cut through the noise, translating the latest breaking data and complex science into high-yield, practical insights. Whether you are https://t.co/isBsTVnEcK
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 2 days ago
#OP0337 In 48-week WILLOW🌳 LTE, oral TLR7/8 inhibitor enpatoran showed sustained improvements in cutaneous lupus activity with high CLASI-50/70 response rates and consistent safety profile across doses. Encouraging long-term data for CLE/SLE skin disease. #EULAR2026 @RheumNow https://t.co/6y0HjaTMqh
Mrinalini Dey @DrMiniDey ( View Tweet )
2 weeks 2 days ago
#EULAR2026 OP0337 In double blind LTE WILLOW study, cutaneous efficacy (change in CLASI, CLASI 70/50) was maintained in Enpatoran, TLR 7/8-i by WK48. Those switched from PBO to ENP at WK24 also showed equal efficacy to ENP-ENP group. Promising treatment for #CLE #lupus @RheumNow https://t.co/0Plpy6c8At
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
2 weeks 2 days ago
Personalized #RA treatment based on Ab status and early response: better than routine care? PRIMERA RCT (n=308) says not yet. b/tsDMARD use at 10m: 21% tailored vs 17% routine. Disease activity curves identical. MTX + T2T still the standard for most. @RheumNow #EULAR2026 POS0258 https://t.co/W9FVoqTcMq
Jiha Lee @JihaRheum ( View Tweet )
2 weeks 2 days ago
PET-derived parameters in #PsA correlated with DAPSA, CRP and patient pain. Angiogenesis imaging may be a complementary biomarker of overall disease burden Abstr#OP068 #EULAR2026 #Imaging
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
2 weeks 1 day ago
RheumNow’s expanded coverage of the #EULAR2026 annual meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 2 days ago
One of the main changes in the 2025 update on the EULAR guidelines for imaging in SpA is that of MRI replacing CR as the initial imaging modality while CR & low dose CT of SIJs became alternative modalities in the absence of or if with CIs to MRI
AbsPOS0682 @RheumNow #EULAR2026 https://t.co/bj2NWKnIGf
sheila @RHEUMarampa ( View Tweet )
2 weeks 2 days ago
Treat-to-target in inflammatory arthritis recommended by every guideline. Followed in only 40% of SpA visits.
The main reason was activity simply wasn’t documented using a validated index.
You can’t target what you don’t measure.
Abstr 0351 @ RheumNow #EULAR2026
#axSpA #PsA https://t.co/VAcoZfCXsR
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
2 weeks 2 days ago
#OP0344 RADAR, AI-automated scoring of RA radiographic damage, was applied to 20yr ESPOIR imaging data. Strong performance vs expert readers, w binary classification accuracy up to 0.95 & ICC 0.86. Supports AI-assisted long-term structural assessment in RA. #EULAR2026 @RheumNow
Mrinalini Dey @DrMiniDey ( View Tweet )
2 weeks 2 days ago
New Insights in Gout Clinical Management
https://t.co/Eo63NUhaY2 https://t.co/oHZG1c1LhL
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 1 day ago
CAR-T Cell Therapies in Refractory RMD Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare. Recent anecdotal reports suggest that CD19-directed CAR-T cell therapy may https://t.co/lXX5RjEw6a
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 2 days ago
JAK Safety Debate Continues: Stronger VTE signal, less clear cancer signal
Few topics in rheumatology have reshaped prescribing behavior as dramatically as the safety concerns surrounding JAK inhibitors following ORAL Surveillance and the subsequent FDA and EMA warnings. Even https://t.co/wfQZn1hO3N
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 3 days ago
